Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives

References

• Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis. 2014;8(4):288–295. doi:10.1016/j.crohns.2013.09.00124074875
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727. doi:10.1038/nrgastro.2015.15026323879
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–217. doi:10.1038/nrgastro.2015.3425732745
   PubMed Web of Science ®Google Scholar
• Francescone R, Hou V, Grivennikov SI, Cytokines IBD. colitis-associated cancer. Inflamm Bowel Dis. 2015;21(2):409–418. doi:10.1097/MIB.000000000000023625563695
   PubMed Web of Science ®Google Scholar
• Beaugerie L. [IBD and increased risk of cancer: what is the reality?]. Rev Infirm. 2014;63(199):28. doi:10.1016/j.revinf.2013.12.011
   Google Scholar
• Stormont JM, Shah AN, Sharma AK, Saubermann LJ, Farmer RG. Colorectal cancer in IBD patients. Am J Gastroenterol. 2013;108(9):1535. doi:10.1038/ajg.2013.203
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-029050646
   PubMed Web of Science ®Google Scholar
• Venkataraman GR, Rivas MA. Rare and common variant discovery in complex disease: the IBD case study. Hum Mol Genet. 2019. doi:10.1093/hmg/ddz189
   PubMed Web of Science ®Google Scholar
• Hammer T, Lophaven SN, Nielsen KR, et al. Dietary risk factors for inflammatory bowel diseases in a high-risk population: results from the Faroese IBD study. United Eur Gastroenterol J. 2019;7(7):924–932. doi:10.1177/2050640619852244
   PubMed Web of Science ®Google Scholar
• Kaplan GG. IBD: global variations in environmental risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2014;11(12):708–709. doi:10.1038/nrgastro.2014.18225348851
   PubMedGoogle Scholar
• van der Sloot KWJ, Weersma RK, Dijkstra G, Alizadeh BZ. Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ). J Gastroenterol. 2019;54(3):238–248. doi:10.1007/s00535-018-1501-z30109418
   PubMed Web of Science ®Google Scholar
• Lim JS, Lim MY, Choi Y, Ko G. Modeling environmental risk factors of autism in mice induces IBD-related gut microbial dysbiosis and hyperserotonemia. Mol Brain. 2017;10(1):14. doi:10.1186/s13041-017-0292-028427452
   PubMedGoogle Scholar
• Putignani L, Del Chierico F, Vernocchi P, et al. Gut microbiota dysbiosis as risk and premorbid factors of IBD and IBS along the childhood-adulthood transition. Inflamm Bowel Dis. 2016;22(2):487–504. doi:10.1097/MIB.000000000000060226588090
   PubMedGoogle Scholar
• Zhang M, Merlin D. Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24(7):1401–1415. doi:10.1093/ibd/izy12329788186
   PubMed Web of Science ®Google Scholar
• Sabino J, Verstockt B, Vermeire S, Ferrante M. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol. 2019;12:1756284819853208. doi:10.1177/1756284819853208
   Web of Science ®Google Scholar
• Zeeshan M, Ali H, Khan S, Mukhtar M, Khan MI, Arshad M. Glycyrrhizic acid-loaded pH-sensitive poly-(lactic-co-glycolic acid) nanoparticles for the amelioration of inflammatory bowel disease. Nanomedicine (Lond). 2019;14(15):1945–1969. doi:10.2217/nnm-2018-041531355705
   PubMed Web of Science ®Google Scholar
• Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn’s disease: optimising the old and maximising the new. F1000Research. 2019;8. doi:10.12688/f1000research.18902.1
   PubMedGoogle Scholar
• Zhang S, Langer R, Traverso G. Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. Nano Today. 2017;16:82–96. doi:10.1016/j.nantod.2017.08.00631186671
   PubMed Web of Science ®Google Scholar
• Mokhtarzadeh A, Hassanpour S, Vahid ZF, et al. Nano-delivery system targeting to cancer stem cell cluster of differentiation biomarkers. J Control Release. 2017;266:166–186. doi:10.1016/j.jconrel.2017.09.02828941992
   PubMed Web of Science ®Google Scholar
• D’Inca R, Paccagnella M, Cardin R, et al. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol. 2013;19(34):5665–5670. doi:10.3748/wjg.v19.i34.566524039359
   PubMedGoogle Scholar
• Viscido A, Capannolo A, Latella G, Caprilli R, Frieri G. Nanotechnology in the treatment of inflammatory bowel diseases. J Crohns Colitis. 2014;8(9):903–918. doi:10.1016/j.crohns.2014.02.02424686095
   PubMed Web of Science ®Google Scholar
• Huang Z, Gan J, Jia L, et al. An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Biomaterials. 2015;48:26–36. doi:10.1016/j.biomaterials.2015.01.01325701029
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158–171. doi:10.1016/j.addr.2008.11.00219133304
   PubMed Web of Science ®Google Scholar
• Takedatsu H, Mitsuyama K, Torimura T. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11343–11352. doi:10.3748/wjg.v21.i40.1134326525603
   PubMedGoogle Scholar
• Lu L, Chen G, Qiu Y, et al. Nanoparticle-based oral delivery systems for colon targeting: principles and design strategies. Sci Bull. 2016;61(9):670–681. doi:10.1007/s11434-016-1056-4
   Web of Science ®Google Scholar
• Xia F, Ding F, Lv Y, Di W, Sheng Y, Ding G. A high efficient method to isolate exosomes from small intestinal epithelium. Mol Biotechnol. 2019;61(5):325–331. doi:10.1007/s12033-019-00163-930796724
   PubMedGoogle Scholar
• Regueiro M, Swoger J. Clinical Challenges and Complications of IBD. Thorofare, NJ: SLACK Inc.; 2013.
   Google Scholar
• Melero A, Draheim C, Hansen S, et al. Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Eur J Pharma Biopharm. 2017;119:361–371. doi:10.1016/j.ejpb.2017.07.004
   PubMed Web of Science ®Google Scholar
• Chassaing B, Gewirtz AT. Identification of inner mucus-associated bacteria by laser capture microdissection. Cell Mol Gastroenterol Hepatol. 2019;7(1):157–160. doi:10.1016/j.jcmgh.2018.09.00930510996
   PubMedGoogle Scholar
• Irache JM, Durrer C, Duchene D, Ponchel G. Bioadhesion of lectin-latex conjugates to rat intestinal mucosa. Pharm Res. 1996;13(11):1716–1719. doi:10.1023/A:10164051266568956340
   PubMed Web of Science ®Google Scholar
• Juge N. Microbial adhesins to gastrointestinal mucus. Trends Microbiol. 2012;20(1):30–39. doi:10.1016/j.tim.2011.10.00122088901
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Loening-Baucke V, Theissig F, et al. Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut. 2007;56(3):343–350. doi:10.1136/gut.2006.09816016908512
   PubMed Web of Science ®Google Scholar
• Qin X. Damage of the mucus layer: the possible shared critical common cause for Both Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). Inflamm Bowel Dis. 2017;23(2):E11–E12. doi:10.1097/MIB.000000000000101028079624
   PubMedGoogle Scholar
• Scaldaferri F, Lopetuso LR, Petito V, et al. Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: emerging role for ‘gut barrier protectors’ in IBD? United Eur Gastroenterol J. 2014;2(2):113–122. doi:10.1177/2050640614520867
   PubMed Web of Science ®Google Scholar
• Des Rieux A, Fievez V, Theate I, Mast J, Preat V, YJ S. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm Sci. 2007;30(5):380–391. doi:10.1016/j.ejps.2006.12.00617291730
   PubMed Web of Science ®Google Scholar
• Greish K, Taha S, Jasim A, et al. Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease. Clin Transl Med. 2017;6(1):28. doi:10.1186/s40169-017-0157-228770521
   PubMedGoogle Scholar
• Iglesias N, Galbis E, Diaz-Blanco MJ, Lucas R, Benito E, de-Paz MV. Nanostructured chitosan-based biomaterials for sustained and colon-specific resveratrol release. Int J Mol Sci. 2019;20(2):398. doi:10.3390/ijms20020398
   PubMed Web of Science ®Google Scholar
• Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628–1640. doi:10.1016/j.ymthe.2016.11.02028143741
   PubMed Web of Science ®Google Scholar
• Xiao J, Feng S, Wang X, et al. Identification of exosome-like nanoparticle-derived microRNAs from 11 edible fruits and vegetables. PeerJ. 2018;6:e5186. doi:10.7717/peerj.518630083436
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang M, Merlin D. Advances in plant-derived edible nanoparticle-based lipid nano-drug delivery systems as therapeutic nanomedicines. J Mater Chem B. 2018;6(9):1312–1321. doi:10.1039/C7TB03207B30034807
   PubMed Web of Science ®Google Scholar
• Charania MA, Laroui H, Liu H, et al. Intestinal epithelial CD98 directly modulates the innate host response to enteric bacterial pathogens. Infect Immun. 2013;81(3):923–934. doi:10.1128/IAI.01388-1223297381
   PubMed Web of Science ®Google Scholar
• Xiao B, Laroui H, Viennois E, et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014;146(5):1289–1300e, 1281–1219. doi:10.1053/j.gastro.2014.01.056
   PubMed Web of Science ®Google Scholar
• Zucchelli M, Torkvist L, Bresso F, et al. PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(10):1562–1569. doi:10.1002/ibd.2096319462432
   PubMedGoogle Scholar
• Wang Y, Hu Y, Li P, et al. Expression and regulation of proton-coupled oligopeptide transporters in colonic tissue and immune cells of mice. Biochem Pharmacol. 2018;148:163–173. doi:10.1016/j.bcp.2017.12.02529305856
   PubMedGoogle Scholar
• Wang CY, Liu S, Xie XN, Tan ZR. Regulation profile of the intestinal peptide transporter 1 (PepT1). Drug Des Devel Ther. 2017;11:3511–3517. doi:10.2147/DDDT.S151725
   PubMed Web of Science ®Google Scholar
• Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. doi:10.1053/j.gastro.2007.10.02618061177
   PubMed Web of Science ®Google Scholar
• Wu Y, Sun M, Wang D, et al. A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis. Biomater Sci. 2019;7:4299–4309. doi:10.1039/C9BM00925F31408067
   PubMedGoogle Scholar
• Pellegrini C, Antonioli L, Colucci R, Blandizzi C, Fornai M. Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? Acta Neuropathol. 2018;136(3):345–361.29797112
   PubMed Web of Science ®Google Scholar
• Haag LM, Siegmund B. Intestinal microbiota and the innate immune system - a crosstalk in Crohn’s disease pathogenesis. Front Immunol. 2015;6:489. doi:10.3389/fimmu.2015.0048926441993
   PubMed Web of Science ®Google Scholar
• Santiago L, Castro M, Pardo J, Arias M. Mouse model of Colitis-Associated Colorectal Cancer (CAC): isolation and characterization of mucosal-associated lymphoid cells. Methods Mol Biol. 2019;1884:189–202.30465204
   PubMedGoogle Scholar
• Matsui F, Inaba M, Uchida K, et al. Induction of PIR-A/B(+) DCs in the in vitro inflammatory condition and their immunoregulatory function. J Gastroenterol. 2018;53(10):1131–1141. doi:10.1007/s00535-018-1447-129508072
   PubMedGoogle Scholar
• Schoultz I, Keita AV. Cellular and molecular therapeutic targets in inflammatory bowel disease-focusing on intestinal barrier function. Cells. 2019;8(2):193. doi:10.3390/cells8020193
   PubMed Web of Science ®Google Scholar
• Butin-Israeli V, Bui TM, Wiesolek HL, et al. Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing. J Clin Invest. 2019;129(2):712–726.30640176
   PubMed Web of Science ®Google Scholar
• Shimshoni E, Yablecovitch D, Baram L, Dotan I, Sagi I. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut. 2015;64(3):367–372. doi:10.1136/gutjnl-2014-30804825416065
   PubMed Web of Science ®Google Scholar
• Lindholm M, Manon-Jensen T, Madsen GI, et al. Extracellular matrix fragments of the basement membrane and the interstitial matrix are serological markers of intestinal tissue remodeling and disease activity in dextran sulfate sodium colitis. Dig Dis Sci. 2019. doi:10.1007/s10620-019-05676-6
   PubMed Web of Science ®Google Scholar
• Stronati L, Palone F, Negroni A, et al. Dipotassium glycyrrhizate improves intestinal mucosal healing by modulating extracellular matrix remodeling genes and restoring epithelial barrier functions. Front Immunol. 2019;10:939. doi:10.3389/fimmu.2019.0093931105713
   PubMedGoogle Scholar
• Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol. 2008;180(8):5662–5669. doi:10.4049/jimmunol.180.8.566218390751
   PubMed Web of Science ®Google Scholar
• Ajdukovic J, Salamunic I, Hozo I, et al. Soluble P-selectin glycoprotein ligand - a possible new target in ulcerative colitis. Bratisl Lek Listy. 2015;116(3):147–149.25869560
   PubMed Web of Science ®Google Scholar
• Weishaupt C, Steinert M, Brunner G, et al. Activation of human vascular endothelium in melanoma metastases induces ICAM-1 and E-selectin expression and results in increased infiltration with effector lymphocytes. Exp Dermatol. 2019. doi:10.1111/exd.14023
   PubMed Web of Science ®Google Scholar
• Jin K, Luo Z, Zhang B, Pang Z. Biomimetic nanoparticles for inflammation targeting. Acta Pharma Sin B. 2018;8(1):23–33. doi:10.1016/j.apsb.2017.12.002
   PubMed Web of Science ®Google Scholar
• Farzi B, Young D, Scrimgeour J, Cetinkaya C. Mechanical properties of P-selectin PSGL-1 bonds. Colloids Surf B Biointerfaces. 2019;173:529–538. doi:10.1016/j.colsurfb.2018.10.01730342396
   PubMedGoogle Scholar
• Sakhalkar HS, Dalal MK, Salem AK, et al. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci U S A. 2003;100(26):15895–15900. doi:10.1073/pnas.263143310014668435
   PubMed Web of Science ®Google Scholar
• Eniola AO, Hammer DA. Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes II: effect of degradation on targeting activity. Biomaterials. 2005;26(6):661–670. doi:10.1016/j.biomaterials.2004.03.00315282144
   PubMedGoogle Scholar
• Eniola AO, Rodgers SD, Hammer DA. Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes. Biomaterials. 2002;23(10):2167–2177. doi:10.1016/S0142-9612(01)00349-011962658
   PubMedGoogle Scholar
• Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008;319(5863):627–630. doi:10.1126/science.114985918239128
   PubMed Web of Science ®Google Scholar
• Vieira AC, Chaves LL, Pinheiro M, Ferreira D, Sarmento B, Reis S. Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells. Int J Nanomedicine. 2016;11:2601–2617. doi:10.2147/IJN.S10490827354792
   PubMed Web of Science ®Google Scholar
• Huang Y, Guo J, Gui S. Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-a siRNA provide a novel strategy for the experimental treatment of ulcerative colitis. Eur J Pharm Sci. 2018;125:232–243. doi:10.1016/j.ejps.2018.10.00930315858
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Z, Chen B, Gu L, Li Y, Yu S. Design and evaluation of galactosylated chitosan/graphene oxide nanoparticles as a drug delivery system. J Colloid Interface Sci. 2018;516:332–341. doi:10.1016/j.jcis.2018.01.07329408121
   PubMed Web of Science ®Google Scholar
• Zhang J, Tang C, Yin C. Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages. Biomaterials. 2013;34(14):3667–3677. doi:10.1016/j.biomaterials.2013.01.07923419643
   PubMed Web of Science ®Google Scholar
• Laroui H, Viennois E, Xiao B, et al. Fab’-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release. 2014;186:41–53. doi:10.1016/j.jconrel.2014.04.04624810114
   PubMed Web of Science ®Google Scholar
• Wang B, Zhuang X, Deng ZB, et al. Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther. 2014;22(3):522–534. doi:10.1038/mt.2013.19023939022
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhuang X, Mu J, et al. Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. Nat Commun. 2013;4:1867–1877. doi:10.1038/ncomms288623695661
   PubMed Web of Science ®Google Scholar
• Ma ZJ, Wang YH, Li ZG, et al. Immunosuppressive effect of exosomes from mesenchymal stromal cells in defined medium on experimental colitis. Int J Stem Cells. 2019. doi:10.15283/ijsc18139
   Web of Science ®Google Scholar
• Cai Z, Zhang W, Yang F, et al. Immunosuppressive exosomes from TGF-beta1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res. 2012;22(3):607–610. doi:10.1038/cr.2011.19622157651
   PubMedGoogle Scholar
• Khan I, Ullah N, Zha L, et al. Alteration of gut microbiota in Inflammatory Bowel Disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. 2019;8(3):126. doi:10.3390/pathogens8030126
   PubMed Web of Science ®Google Scholar
• Vieira-Silva S, Sabino J, Valles-Colomer M, et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. Nat Microbio. 2019. doi:10.1038/s41564-019-0483-9
   Web of Science ®Google Scholar
• Sun Y, Li L, Xia Y, et al. The gut microbiota heterogeneity and assembly changes associated with the IBD. Sci Rep. 2019;9(1):440. doi:10.1038/s41598-018-37143-z30679676
   PubMedGoogle Scholar
• Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2019;1–14. doi:10.1080/15548627.2019.1635384
   Web of Science ®Google Scholar
• Holota Y, Dovbynchuk T, Kaji I, et al. The long-term consequences of antibiotic therapy: role of colonic short-chain fatty acids (SCFA) system and intestinal barrier integrity. PLoS One. 2019;14(8):e0220642. doi:10.1371/journal.pone.022064231437166
   PubMedGoogle Scholar
• Liu M, Nazzal L. Enteric hyperoxaluria: role of microbiota and antibiotics. Curr Opin Nephrol Hypertens. 2019;28(4):352–359. doi:10.1097/MNH.000000000000051831145706
   PubMedGoogle Scholar
• Anderson EM, Noble ML, Garty S, et al. Sustained release of antibiotic from poly(2-hydroxyethyl methacrylate) to prevent blinding infections after cataract surgery. Biomaterials. 2009;30(29):5675–5681. doi:10.1016/j.biomaterials.2009.06.04719631376
   PubMedGoogle Scholar
• Gao P, Nie X, Zou M, Shi Y, Cheng G. Recent advances in materials for extended-release antibiotic delivery system. J Antibiot (Tokyo). 2011;64(9):625–634. doi:10.1038/ja.2011.5821811264
   PubMed Web of Science ®Google Scholar
• Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289(5483):1352–1355. doi:10.1126/science.289.5483.135210958782
   PubMed Web of Science ®Google Scholar
• Foligne B, Dessein R, Marceau M, et al. Prevention and treatment of colitis with lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology. 2007;133(3):862–874. doi:10.1053/j.gastro.2007.06.01817678918
   PubMed Web of Science ®Google Scholar
• Souza BM, Preisser TM, Pereira VB, et al. Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells. Microb Cell Fact. 2016;15(1):150. doi:10.1186/s12934-016-0548-x27576902
   PubMedGoogle Scholar
• Bellavia M, Rappa F, Lo Bello M, et al. Lactobacillus casei and bifidobacterium lactis supplementation reduces tissue damage of intestinal mucosa and liver after 2,4,6-trinitrobenzenesulfonic acid treatment in mice. J Biol Regul Homeost Agents. 2014;28(2):251–261.25001657
   PubMed Web of Science ®Google Scholar
• Llopis M, Antolin M, Carol M, et al. Lactobacillus casei downregulates commensals’ inflammatory signals in Crohn’s disease mucosa. Inflamm Bowel Dis. 2009;15(2):275–283. doi:10.1002/ibd.2073618839424
   PubMedGoogle Scholar
• Kim MS, Byun JS, Yoon YS, Yum DY, Chung MJ, Lee JC. A probiotic combination attenuates experimental colitis through inhibition of innate cytokine production. Benef Microbes. 2017;8(2):231–241. doi:10.3920/BM2016.003128008786
   PubMedGoogle Scholar
• Kawahara M, Nemoto M, Nakata T, et al. Anti-inflammatory properties of fermented soy milk with lactococcus lactis subsp. lactis S-SU2 in murine macrophage RAW264.7 cells and DSS-induced IBD model mice. Int Immunopharmacol. 2015;26(2):295–303. doi:10.1016/j.intimp.2015.04.00425887264
   PubMedGoogle Scholar
• Ricci S, Macchia G, Ruggiero P, et al. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol. 2003;3:15. doi:10.1186/1472-6750-3-1513129437
   PubMedGoogle Scholar
• Teng Y, Ren Y, Sayed M, et al. Plant-Derived exosomal MicroRNAs shape the gut microbiota. Cell Host Microbe. 2018;24(5):637–652 e638. doi:10.1016/j.chom.2018.10.00130449315
   PubMed Web of Science ®Google Scholar
• Nguyen MA, Wyatt H, Susser L, et al. Delivery of MicroRNAs by Chitosan nanoparticles to functionally alter macrophage cholesterol efflux in vitro and in vivo. ACS Nano. 2019;13(6):6491–6505. doi:10.1021/acsnano.8b0967931125197
   PubMed Web of Science ®Google Scholar
• Petkau K, Kaeser A, Fischer I, Brunsveld L, Schenning AP. Pre- and postfunctionalized self-assembled pi-conjugated fluorescent organic nanoparticles for dual targeting. J Am Chem Soc. 2011;133(42):17063–17071. doi:10.1021/ja207534521913650
   PubMedGoogle Scholar
• Gao C, Liu L, Zhou Y, Bian Z, Wang S, Wang Y. Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease. Chin Med. 2019;14:23. doi:10.1186/s13020-019-0245-x31236131
   PubMed Web of Science ®Google Scholar
• Gazzaniga A, Maroni A, Foppoli A, Palugan L. Oral colon delivery: rationale and time-based drug design strategy. Discov Med. 2006;6(36):223–228.17250787
   PubMedGoogle Scholar
• Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4(3):160–170. doi:10.1038/ncpgasthep069617339853
   PubMedGoogle Scholar
• Ali H, Weigmann B, Neurath MF, Collnot EM, Windbergs M, Lehr CM. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Control Release. 2014;183:167–177. doi:10.1016/j.jconrel.2014.03.03924685705
   PubMed Web of Science ®Google Scholar
• Zhang M, Xiao B, Wang H, et al. Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy. Mol Ther. 2016;24(10):1783–1796. doi:10.1038/mt.2016.15927491931
   PubMed Web of Science ®Google Scholar
• Deng Z, Rong Y, Teng Y, et al. Broccoli-derived nanoparticle inhibits mouse colitis by activating dendritic cell AMP-activated protein kinase. Mol Ther. 2017;25(7):1641–1654. doi:10.1016/j.ymthe.2017.01.02528274798
   PubMed Web of Science ®Google Scholar
• Li W, Zhang T, Ye Y, Zhang X, Wu B. Enhanced bioavailability of tripterine through lipid nanoparticles using broccoli-derived lipids as a carrier material. Int J Pharm. 2015;495(2):948–955. doi:10.1016/j.ijpharm.2015.10.01126453780
   PubMed Web of Science ®Google Scholar
• Wang QL, Zhuang X, Sriwastva MK, et al. Blood exosomes regulate the tissue distribution of grapefruit-derived nanovector via CD36 and IGFR1 pathways. Theranostics. 2018;8(18):4912–4924.30429877
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang X, Han MK, Collins JF, Merlin D. Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine (Lond). 2017;12(16):1927–1943. doi:10.2217/nnm-2017-019628665164
   PubMed Web of Science ®Google Scholar
• Trinchard-Lugan I, Ho-Nguyen Q, Bilham WM, Buraglio M, Ythier A, Munafo A. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Eur Cytokine Netw. 2001;12(3):391–398.11566619
   PubMed Web of Science ®Google Scholar
• Gendelman HE, Zhang Y, Santamaria P, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial. NPJ Parkinsons Dis. 2017;3:10. doi:10.1038/s41531-017-0013-528649610
   PubMed Web of Science ®Google Scholar
• Spitler LE, Cao H, Piironen T, Whiteside TL, Weber RW, Cruickshank S. Biological effects of anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody formation in patients treated with GM-CSF (Sargramostim) as adjuvant therapy of melanoma. Am J Clin Oncol. 2017;40(2):207–213. doi:10.1097/COC.000000000000012425286079
   PubMedGoogle Scholar
• Hu X, Li D, Gao Y, Mu L, Zhou Q. Knowledge gaps between nanotoxicological research and nanomaterial safety. Environ Int. 2016;94:8–23. doi:10.1016/j.envint.2016.05.00127203780
   PubMed Web of Science ®Google Scholar
• Boverhof DR, Bramante CM, Butala JH, et al. Comparative assessment of nanomaterial definitions and safety evaluation considerations. Regul Toxicol Pharmacol. 2015;73(1):137–150. doi:10.1016/j.yrtph.2015.06.00126111608
   PubMed Web of Science ®Google Scholar
• Can Demirdogen B. Potential role of calcifying nanoparticles in the etiology of multiple sclerosis. Med Hypotheses. 2019;128:25–27. doi:10.1016/j.mehy.2019.05.00531203904
   PubMedGoogle Scholar
• Roach KA, Stefaniak AB, Roberts JR. Metal nanomaterials: immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease. J Immunotoxicol. 2019;16(1):87–124. doi:10.1080/1547691X.2019.160555331195861
   PubMed Web of Science ®Google Scholar
• Olivares-Navarrete R, Hyzy SL, Slosar PJ, Schneider JM, Schwartz Z, Boyan BD. Implant materials generate different peri-implant inflammatory factors: poly-ether-ether-ketone promotes fibrosis and microtextured titanium promotes osteogenic factors. Spine. 2015;40(6):399–404. doi:10.1097/BRS.000000000000077825584952
   PubMedGoogle Scholar
• van den Brule S, Beckers E, Chaurand P, et al. Nanometer-long Ge-imogolite nanotubes cause sustained lung inflammation and fibrosis in rats. Part Fibre Toxicol. 2014;11:67. doi:10.1186/s12989-014-0067-z25497478
   PubMedGoogle Scholar
• Domenis R, Cif A, Fabris M, Curcio F. JOINT MEETING OF PATHOLOGY AND LABORATORY MEDICINE SIPMET. Clinical applications of microenvironment-controlled immunosuppressive properties of mesenchymal stem cells-derived exosomes: a review. Journal of biological regulators and homeostatic agents. Jul-Aug 2018;32 (4 Suppl. 1):15–20.
   Google Scholar
• Wang Y, Tian J, Tang X, et al. Exosomes released by granulocytic myeloid-derived suppressor cells attenuate DSS-induced colitis in mice. Oncotarget. 2016;7(13):15356–15368. doi:10.18632/oncotarget.732426885611
   PubMedGoogle Scholar
• Su H, Cong X, Liu YL. Transplantation of granulocytic myeloid-derived suppressor cells (G-MDSCs) could reduce colitis in experimental murine models. J Dig Dis. 2013;14(5):251–258. doi:10.1111/1751-2980.1202923279711
   PubMedGoogle Scholar
• Wolk O, Epstein S, Ioffe-Dahan V, Ben-Shabat S, Dahan A. New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities. Expert Opin Drug Deliv. 2013;10(9):1275–1286. doi:10.1517/17425247.2013.80048023721560
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon GL, Zimmermann EM. Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update. Expert Rev Clin Immunol. 2010;6(4):543–550. doi:10.1586/eci.10.3020594127
   PubMed Web of Science ®Google Scholar
• Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev. 2005;57(2):267–279. doi:10.1016/j.addr.2004.08.00715555742
   PubMed Web of Science ®Google Scholar
• Zuo L, Huang Z, Dong L, et al. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut. 2010;59(4):470–479. doi:10.1136/gut.2009.18455619951904
   PubMed Web of Science ®Google Scholar
• Bai A, Hu P, Chen J, et al. Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis. Int J Colorectal Dis. 2007;22(6):625–635. doi:10.1007/s00384-006-0229-z17089128
   PubMedGoogle Scholar
• Kesharwani SS, Ahmad R, Bakkari MA, et al. Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): formulation development, characterization and pharmacological evaluation. J Control Release. 2018;290:165–179. doi:10.1016/j.jconrel.2018.08.00430142410
   PubMed Web of Science ®Google Scholar
• Dogra P, Adolphi NL, Wang Z, et al. Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics. Nat Commun. 2018;9(1):4551. doi:10.1038/s41467-018-06730-z30382084
   PubMedGoogle Scholar
• Mohammad AK, Reineke J. Quantitative nanoparticle organ disposition by gel permeation chromatography. Methods Mol Biol. 2012;926:361–367.22975975
   PubMedGoogle Scholar
• Xiao B, Ma L, Merlin D. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opin Drug Deliv. 2017;14(1):65–73. doi:10.1080/17425247.2016.120558327337289
   PubMed Web of Science ®Google Scholar
• Tng DJ, Song P, Lin G, et al. Synthesis and characterization of multifunctional hybrid-polymeric nanoparticles for drug delivery and multimodal imaging of cancer. Int J Nanomedicine. 2015;10:5771–5786. doi:10.2147/IJN.S8646826396511
   PubMed Web of Science ®Google Scholar
• Zhang W, Jiang X, Bao J, Wang Y, Liu H, Tang L. Exosomes in pathogen infections: a bridge to deliver molecules and link functions. Front Immunol. 2018;9:90. doi:10.3389/fimmu.2018.0009029483904
   PubMed Web of Science ®Google Scholar
• Kim SH, Bianco N, Menon R, et al. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther. 2006;13(2):289–300. doi:10.1016/j.ymthe.2005.09.01516275099
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ruemmele FM, Wu GD. Nutrition, Gut Microbiota and Immunity: Therapeutic Targets for IBD. Nestlé Nutrition Institute; 2013.
   Google Scholar
• Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 2015;7(4):2839–2849. doi:10.3390/nu704283925875123
   PubMed Web of Science ®Google Scholar
• Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–573. doi:10.1126/science.124116523828891
   PubMed Web of Science ®Google Scholar
• Katsuma M, Watanabe S, Kawai H, Takemura S, Masuda Y, Fukui M. Studies on lactulose formulations for colon-specific drug delivery. Int J Pharm. 2002;249(1–2):33–43. doi:10.1016/S0378-5173(02)00429-512433432
   PubMedGoogle Scholar
• Abinusawa A, Tenjarla S. Release of 5-Aminosalicylic Acid (5-ASA) from mesalamine formulations at various pH levels. Adv Ther. 2015;32(5):477–484. doi:10.1007/s12325-015-0206-425951927
   PubMedGoogle Scholar
• Yu A, Baker JR, Fioritto AF, et al. Measurement of in vivo gastrointestinal release and dissolution of three locally acting mesalamine formulations in regions of the human gastrointestinal tract. Mol Pharm. 2017;14(2):345–358. doi:10.1021/acs.molpharmaceut.6b0064128009518
   PubMedGoogle Scholar
• Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX((R)) mesalamine. Clin Pharmacol. 2012;4:41–50. doi:10.2147/CPAA.S2655622888278
   PubMedGoogle Scholar
• Goyanes A, Hatton GB, Merchant HA, Basit AW. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations. Int J Pharm. 2015;484(1–2):103–108. doi:10.1016/j.ijpharm.2015.02.05125721685
   PubMed Web of Science ®Google Scholar
• Nicholls A, Harris-Collazo R, Huang M, Hardiman Y, Jones R, Moro L. Bioavailability profile of Uceris MMX extended-release tablets compared with entocort EC capsules in healthy volunteers. J Int Med Res. 2013;41(2):386–394. doi:10.1177/030006051347658823569029
   PubMed Web of Science ®Google Scholar
• Sinha SR, Nguyen LP, Inayathullah M, et al. A thermo-sensitive delivery platform for topical administration of inflammatory bowel disease therapies. Gastroenterology. 2015;149(1):52–55 e52. doi:10.1053/j.gastro.2015.04.00225863215
   PubMed Web of Science ®Google Scholar
• Watts P, Smith A. TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract. Expert Opin Drug Deliv. 2005;2(1):159–167. doi:10.1517/17425247.2.1.15916296742
   PubMedGoogle Scholar